Dataset opportunity
Isa Pharma — Gelegenheid voor medische beeldvormingsdataset
Matige medische beeldvormingsdataset in bezit van Isa Pharma, bruikbaar voor diagnostische AI en computervisie.
Score
67.8
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global AI in Medical Imaging Market to reach US$ 16.88 Billion by 2034 from US$ 1.70 Billion in 2024, growing at a CAGR of 25.8%.
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- 📝Published article
Scientific publications detailing clinical and immunological outcomes
source ↗
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Periodic
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Isa Pharma bezit een zeer gespecialiseerde Medical Imaging Dataset afkomstig uit haar klinische onderzoeken, met beeldmodaliteiten zoals CT en MRI. Deze dataset is uniek verrijkt met bijbehorende immunologische en genomische gegevens, medische dossiers en regelgevende documentatie, waardoor deze uitzonderlijk geschikt is voor het ontwikkelen en valideren van geavanceerde Diagnostic AI modellen, met name in oncologie en immunologie.
De wereldwijde markt voor AI in medische beeldvorming breidt zich snel uit, met een verwachte groei van USD 1,70 miljard in 2024 naar USD 16,88 miljard tegen 2034, met een CAGR van 25,8%. Hoewel toegang onderworpen is aan GDPR en mogelijke overeenkomsten voor gedeeld eigendom, bieden de zeldzaamheid en diepte van deze multimodale gegevens een significant concurrentievoordeel voor entiteiten die willen leiden in de precisiegeneeskunde en diagnostische AI-ruimte, wat de onderhandeling over toegang rechtvaardigt. ⚠ Zorgvuldigheid (waardevolle gegevens, toegang om te onderhandelen): Gegevens uit klinische onderzoeken zijn onderworpen aan strikte medische privacyregelgeving (GDPR).; Gegevens eigendom kan gedeeld worden in specifieke co-ontwikkelingsprogramma's (bv. met Regeneron).; Zeer gespecialiseerde immunologische en genomische datasets die deskundige interpretatie vereisen. · corporate: onafhankelijk.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
Dit bewijs toont gezamenlijk aan dat Isa Pharma een zeldzame, propriëtaire dataset bezit uit haar immunotherapie klinische onderzoeken, die patiënt biomarkers en immuunsysteemreacties koppelt aan concrete behandelingsresultaten. Dit is een cruciaal bezit voor medische AI-bedrijven die de volgende generatie diagnostic AI ontwikkelen om de reactie van patiënten op specifieke kankertherapieën te voorspellen. In een markt die naar verwachting met meer dan 25% per jaar zal groeien, biedt deze unieke gegevens over HPV16-positieve kankers een significant concurrentievoordeel voor het trainen en valideren van voorspellende algoritmen in de oncologie.
See dimension details ↓- Dataset Specificity90
dominant 'medical_records', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
periodic
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
Buyer demand is extremely high, driven by the fierce competition in the AI in Medical Imaging market which is projected to grow at a CAGR of 25.8%, creating urgent demand for unique, high-quality training data.
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
high difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=company_owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation39
1 data-appetite signals (1 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ good target — ISA Pharmaceuticals is a clinical-stage immunotherapy SME developing therapies for cancer and viral infections; the clinical trial data it generates, including medical imaging, is a valuable by-product of its core business, making it an ideal target. Issues: Pitchbook lists the company as 'Out of Business', which contradicts all other sources and recent news, but this should be clarified.
- Deep Qualification90
⚠ needs review — The target is a clinical-stage immunotherapy company whose R&D generates a highly valuable dataset (imaging, genomic, immunologic), but data access is severely restricted by regulatory frameworks (GDPR) and a complex partnership history with Regeneron, which recently ended for the lead asset. [licensing restricted]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
The company holds structured data from Phase I and II clinical trials, detailing patient response, safety, and efficacy metrics essential for training AI to predict treatment outcomes in oncology.
Industrial data
This represents proprietary data detailing T-cell responses and immune system activation, providing a unique longitudinal view crucial for AI models that aim to understand the mechanisms of immunotherapy efficacy.
Regulatory records
The dataset includes deep molecular and biomarker characterizations of trial participants, providing the granular, patient-level data necessary to develop and validate AI algorithms that can identify likely responders to therapy.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Isa Pharma Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging Market to reach US$ 16.88 Billion by 2034 from US$ 1.70 Billion in 2024, growing at a CAGR of 25.8% (source: Market.us). Investment score 67.8/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Microsure — Gegevensset met Sensortelemetering
View opportunity →gezondheidszorgDocobo — Gelegenheid voor dataset medische beeldvorming
View opportunity →gezondheidszorgFilab — Gegevensset voor Industriële Operaties
View opportunity →Data Academy
Learn before you deal
- Data marketplaces, uitgelegd4 min read
- Data licenties, term per term4 min read
- Zijn uw gegevens geld waard?3 min read